Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

A San Francisco online health company that recently faced local backlash over its donation to President Donald Trump’s inauguration is now in hot water over a Super Bowl ad. Hims & Hers, a telehealth ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain supplements ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications ... they aren’t approved for off-label use. Off-label use and shortages can ...

Novo Nordisk (NYSE:NVO) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...